Despite the role of Yes in regulating the Hippo signaling pathway through phosphorylation of YAP and supporting tumor growth, there are currently only a small proportion of the clinically approved Src kinase family inhibitors that effectively target Yes, such as dasatinib and saracatinib. The gene discussed is YES1; the disease is neoplasm.